NasdaqGM:XENEBiotechs
Is It Too Late To Consider Xenon Pharmaceuticals (XENE) After A 58% One-Year Surge?
Wondering whether Xenon Pharmaceuticals at around US$56 a share still offers value, or if most of the opportunity has already been priced in.
The stock has slipped 0.1% over the past week and 2.9% over the past month, yet it is still up 25.9% year to date and 57.6% over the last year. This can change how you think about both upside and risk.
Recent attention on Xenon has centered on how its share price performance compares with other biotech stocks and what that says about investor...